Related Experiment Video
Updated: Aug 13, 2025
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists
Johanna Bödder1, Leanne M Kok1, Jonathan A Fauerbach2
1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Abstract:
Prostaglandin E2 (PGE2) is an important maturation mediator for dendritic cells (DCs). However, increased PGE2 levels in the tumor exert immunosuppressive effects on DCs by signaling through two E-Prostanoid (EP) receptors: EP2 and EP4. Blocking EP-receptor signaling of PGE2 with antagonists is currently being investigated for clinical applications to enhance anti-tumor immunity. In this study, we investigated a new delivery approach by encapsulating EP2/EP4 antagonists in polymeric nanoparticles. The nanoparticles were characterized for size, antagonist loading, and release. The efficacy of the encapsulated antagonists to block PGE2 signaling was analyzed using monocyte-derived DCs (moDCs). The obtained nanoparticles were sized between 210 and 260 nm. The encapsulation efficacy of the EP2/EP4 antagonists was 20% and 17%, respectively, and was further increased with the co-encapsulation of both antagonists. The treatment of moDCs with co-encapsulation EP2/EP4 antagonists prevented PGE2-induced co-stimulatory marker expression. Even though both antagonists showed a burst release within 15 min at 37 °C, the nanoparticles executed the immunomodulatory effects on moDCs. In summary, we demonstrate the functionality of EP2/EP4 antagonist-loaded nanoparticles to overcome PGE2 modulation of moDCs.
Insights
New nanoparticles effectively deliver EP2/EP4 antagonists to block Prostaglandin E2 (PGE2) immunosuppression in dendritic cells (DCs), enhancing anti-tumor immunity potential.
Area of Science:
- Immunology
- Nanotechnology
- Drug Delivery
Background:
- Prostaglandin E2 (PGE2) promotes dendritic cell (DC) maturation but also causes immunosuppression in tumors via EP2 and EP4 receptors.
- Blocking PGE2 signaling through EP2/EP4 receptors is a strategy to boost anti-tumor immunity.
Purpose of the Study:
- To develop and evaluate polymeric nanoparticles for encapsulating EP2/EP4 antagonists.
- To assess the efficacy of these nanoparticles in overcoming PGE2-mediated immunosuppression of DCs.
Main Methods:
- Polymeric nanoparticles were synthesized to encapsulate EP2/EP4 antagonists.
- Nanoparticles were characterized for size (210-260 nm), loading efficiency (20% EP2, 17% EP4), and release kinetics.
- The immunomodulatory effects were tested on monocyte-derived DCs (moDCs).
Main Results:
- Co-encapsulation of EP2/EP4 antagonists increased loading efficiency.
- Nanoparticle treatment prevented PGE2-induced suppression of co-stimulatory markers on moDCs.
- Despite rapid release, nanoparticles demonstrated effective immunomodulatory function.
Conclusions:
- EP2/EP4 antagonist-loaded nanoparticles are a viable approach to counteract PGE2-induced DC modulation.
- This delivery system shows potential for enhancing anti-tumor immune responses.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...